Technovalia is a privately-owned Australian biotech company dedicated to the research and development of innovative vaccines and diagnostics.

In partnership with several academic organisations and international companies, Technovalia is investing in the development of new technology platforms that have the potential to significantly improve protection against several infectious diseases by producing safer, more stable and more cost-effective vaccines and diagnostics.

 

We believe everyone should have access to safe and effective vaccines and tests against major diseases

Through collaborative efforts with leading Australian academic organisations and Health Networks, we are now advancing rapidly the development and availability of these vaccines for Australians, allowing a rapid and efficient response to pandemic situations.

More than ever, this is the case with the current COVID-19 pandemic the world is experiencing. 

Since March 2020, Technovalia has been working with BioNet-Asia on the development of several gene-based COVID-19 vaccines (COVIGEN), including a DNA-based COVID-19 vaccine (preclinical stage) and a mRNA-based COVID-19 vaccine (research stage).  Technovalia and BioNet-Asia have the expertise and experience required to bring a vaccine to licensure, and the capacity for large-scale production of COVIGEN vaccines according to Good Manufacturing Practices (GMP) PIC/S standards. This collaboration also involves several Australians institutions and companies on the clinical development of COVIGEN and its possible production in Australia.